This winter, medical experts guide you through the latest diagnostic standards, the non-deficiency causes of fatigue, and the practical steps you can take ...
The Observer has compiled a list of 2025 guides, tutorials, and manuals designed to support psychological scientists as they ...
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Praxis Precision (PRAX) announced results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic ...
Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock surged 25% after the company announced its EMBOLD study evaluating relutrigine was stopped early due to positive efficacy results. The ...
Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec.
Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...
Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...
Oct 16 (Reuters) - Praxis Precision Medicines (PRAX.O), opens new tab said on Thursday its experimental drug for a type of movement disorder improved patients' ability to perform daily tasks in two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback